Literature DB >> 23390638

T cells out of control--impaired immune regulation in the inflamed joint.

Ellen J Wehrens1, Berent J Prakken, Femke van Wijk.   

Abstract

Since the discovery of FOXP3+ regulatory T (T(REG)) cells over 15 years ago, intensive research has focused on their presence, phenotype and function in autoimmune disease. Whether deficiencies in T(REG) cells underlie autoimmune pathology and whether, or how, therapeutic approaches based on these cells might be successful is still the subject of debate. The potential role of T(REG)-cell extrinsic factors, such as proinflammatory cytokines and resistance of effector T cells to suppression, as the cause of regulatory defects in chronic autoimmune inflammation is an intensive area of research. It is now clear that, at the site of inflammation, antigen presenting cells (APCs) and proinflammatory cytokines drive effector T cell skewing and plasticity, and that these T cells can become unresponsive to regulation. In addition, expansion and function of T(REG) cells is affected by the inflammatory environment; indeed, new data suggest that, in certain conditions, T(REG) cells promote inflammation. This Review summarizes the latest findings on changes in effector T cell homeostasis in autoimmune disease and focuses on how mechanisms that normally regulate these cells are affected in the inflamed joints of patients with arthritis. These findings have important clinical implications and will affect the development of new therapeutic strategies for autoimmune arthritis.

Entities:  

Mesh:

Year:  2013        PMID: 23390638     DOI: 10.1038/nrrheum.2012.149

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  103 in total

1.  MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus.

Authors:  C R Monk; M Spachidou; F Rovis; E Leung; M Botto; R I Lechler; O A Garden
Journal:  Arthritis Rheum       Date:  2005-04

2.  alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade.

Authors:  Itamar Goldstein; Shomron Ben-Horin; Alexander Koltakov; Helly Chermoshnuk; Victor Polevoy; Yakov Berkun; Ninette Amariglio; Ilan Bank
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

3.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 4.  IL-17 as a future therapeutic target for rheumatoid arthritis.

Authors:  Wim B van den Berg; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

Review 5.  Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.

Authors:  Jagadeesh Bayry; Sophie Sibéril; Frédéric Triebel; David F Tough; Srini V Kaveri
Journal:  Drug Discov Today       Date:  2007-06-27       Impact factor: 7.851

6.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

Authors:  Takahisa Miyao; Stefan Floess; Ruka Setoguchi; Hervé Luche; Hans Joerg Fehling; Herman Waldmann; Jochen Huehn; Shohei Hori
Journal:  Immunity       Date:  2012-02-09       Impact factor: 31.745

7.  Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.

Authors:  Jenny L McGovern; Dao X Nguyen; Clare A Notley; Claudia Mauri; David A Isenberg; Michael R Ehrenstein
Journal:  Arthritis Rheum       Date:  2012-10

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

Review 9.  Cells of the synovium in rheumatoid arthritis. T lymphocytes.

Authors:  Steven K Lundy; Sujata Sarkar; Laura A Tesmer; David A Fox
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  Phenotypic and functional features of human Th17 cells.

Authors:  Francesco Annunziato; Lorenzo Cosmi; Veronica Santarlasci; Laura Maggi; Francesco Liotta; Benedetta Mazzinghi; Eliana Parente; Lucia Filì; Simona Ferri; Francesca Frosali; Francesco Giudici; Paola Romagnani; Paola Parronchi; Francesco Tonelli; Enrico Maggi; Sergio Romagnani
Journal:  J Exp Med       Date:  2007-07-16       Impact factor: 14.307

View more
  44 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Decade in review-paediatric rheumatology: A field on the move.

Authors:  Seza Ozen
Journal:  Nat Rev Rheumatol       Date:  2015-09-22       Impact factor: 20.543

3.  Transcriptional network profile on synovial fluid T cells in psoriatic arthritis.

Authors:  Ugo Fiocco; Veronica Martini; Benedetta Accordi; Francesco Caso; Luisa Costa; Francesca Oliviero; Anna Scanu; Monica Facco; Daniele Boso; Mariele Gatto; Mara Felicetti; Paola Frallonardo; Roberta Ramonda; Lucia Piva; Renato Zambello; Carlo Agostini; Raffaele Scarpa; Giuseppe Basso; Gianpietro Semenzato; Jean-Michel Dayer; Leonardo Punzi; Andrea Doria
Journal:  Clin Rheumatol       Date:  2015-07-09       Impact factor: 2.980

4.  APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patients.

Authors:  Ariana Barberá; Noraylis Lorenzo; Peter van Kooten; Joel van Roon; Wilco de Jager; Dinorah Prada; Jorge Gómez; Gabriel Padrón; Willem van Eden; Femke Broere; María Del Carmen Domínguez
Journal:  Cell Stress Chaperones       Date:  2016-05-30       Impact factor: 3.667

Review 5.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

Review 6.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

Review 7.  Of mice and men: how animal models advance our understanding of T-cell function in RA.

Authors:  Tamás Kobezda; Sheida Ghassemi-Nejad; Katalin Mikecz; Tibor T Glant; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-01-07       Impact factor: 20.543

8.  Program Death-1 Suppresses Autoimmune Arthritis by Inhibiting Th17 Response.

Authors:  Lifen Yang; Guilin Qiao; Yassir Hassan; Zhenping Li; Xiaoqing Zhang; Huimin Kong; Weimin Zeng; Fei Yin; Jian Zhang
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-19       Impact factor: 4.291

Review 9.  [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].

Authors:  K Ohl; K Tenbrock
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

10.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.

Authors:  Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Tomoki Nakashima; Masatsugu Oh-hora; Tatsuhiko Kodama; Sakae Tanaka; Jeffrey A Bluestone; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.